Mouse models of hepatocellular carcinoma

Seminars in Liver Disease

Volumn 30, Issue 1, 2010, Pages 87-98

  Fausto, Nelson ^a   Campbell, Jean S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Conditional inducible gene expression; Hepatocellular carcinoma; Knockout mice; Liver cancer; Transgenic mice

Indexed keywords

CARCINOGEN; CHOLINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIETHYLNITOSAMINE; DOXYCYCLINE; ECDYSONE; ETHIONINE; IMATINIB; LIGAND; MIFEPRISTONE; PLATELET DERIVED GROWTH FACTOR C; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TETRACYCLINE; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

CARCINOGENESIS; DIET; EXPERIMENTAL ANIMAL; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC SCREENING; GENETIC TRANSCRIPTION; HUMAN; INDEL MUTATION; LIVER CELL CARCINOMA; MUTAGENESIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TRANSGENIC MOUSE; TRANSPOSON;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; SPECIES SPECIFICITY;

EID: 77349084445     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0030-1247135     Document Type: Review

References (70)

1. Farber E. Ethionine carcinogenesis. Adv Cancer Res 1963 7 383-474
2. Pitot H C. The natural history of neoplastic development: the relation of experimental models to human cancer. Cancer 1982 49 (6) 1206-1211
3. Price J M., Harman J W., Miller E C., Miller J A. Progressive microscopic alterations in the livers of rats fed the hepatic carcinogens 3-methyl-4-dimethylaminoazobenzene and 4-fluoro-4-dimethylaminoazobenzene. Cancer Res 1952 12 (3) 192-200
4. Solt D B., Cayama E, Tsuda H, Enomoto K, Lee G, Farber E. Promotion of liver cancer development by brief exposure to dietary 2-acetylaminofluorene plus partial hepatectomy or carbon tetrachloride. Cancer Res 1983 43 (1) 188-191
5. Farber E. Similarities in the sequence of early histological changes induced in the liver of the rat by ethionine, 2-acetylamino-fluorene, and 3-methyl-4-dimethylaminoazobenzene. Cancer Res 1956 16 (2) 142-148
6. Fausto N, Campbell J S. The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Dev 2003 120 (1) 117-130
7. Gossen M, Bujard H. Studying gene function in eukaryotes by conditional gene inactivation. Annu Rev Genet 2002 36 153-173
8. Hardouin S N., Nagy A. Mouse models for human disease. Clin Genet 2000 57 (4) 237-244
9. Zender L, Spector M S., Xue W et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006 125 (7) 1253-1267
10. Keng V W., Villanueva A, Chiang D Y. et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol 2009 27 (3) 264-274
11. Hoshida Y, Nijman S M., Kobayashi M et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009 69 (18) 7385-7392
12. Katoh H, Ojima H, Kokubu A et al. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. Gastroenterology 2007 133 (5) 1475-1486
13. Lee J S., Chu I S., Mikaelyan A et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004 36 (12) 1306-1311
14. Boyault S, Rickman D S., de Reynis A et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007 45 (1) 42-52
15. Campbell J S., Johnson M M., Bauer R L. et al. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation 2007 75 (9) 843-852
16. Hoshida Y, Villanueva A, Kobayashi M et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008 359 (19) 1995-2004
17. Heindryckx F, Colle I, Van Vlierberghe H. Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol 2009 90 (4) 367-386
18. Newell P, Villanueva A, Friedman S L., Koike K, Llovet J M. Experimental models of hepatocellular carcinoma. J Hepatol 2008 48 (5) 858-879
19. Lee J S., Grisham J W., Thorgeirsson S S. Comparative functional genomics for identifying models of human cancer. Carcinogenesis 2005 26 (6) 1013-1020
20. Verna L, Whysner J, Williams G M. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther 1996 71 (1-2) 57-81 (Pubitemid 26323290)
21. Kaina B, Christmann M, Naumann S, Roos W P. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007 6 (8) 1079-1099
22. Vesselinovitch S D., Rao K V., Mihailovich N. Neoplastic response of mouse tissues during perinatal age periods and its significance in chemical carcinogenesis. Natl Cancer Inst Monogr 1979 51 (51) 239-250
23. Hacker H J., Mtiro H, Bannasch P, Vesselinovitch S D. Histochemical profile of mouse hepatocellular adenomas and carcinomas induced by a single dose of diethylnitrosamine. Cancer Res 1991 51 (7) 1952-1958
24. Vesselinovitch S D., Hacker H J., Bannasch P. Histochemical characterization of focal hepatic lesions induced by single diethylnitrosamine treatment in infant mice. Cancer Res 1985 45 (6) 2774-2780
25. Vesselinovitch S D., Mihailovich N. Kinetics of diethylnitrosamine hepatocarcinogenesis in the infant mouse. Cancer Res 1983 43 (9) 4253-4259
26. Riehle K J., Campbell J S., McMahan R S. et al. Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. J Exp Med 2008 205 (1) 91-103
27. Ogata H, Kobayashi T, Chinen T et al. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology 2006 131 (1) 179-193
28. Teoh N C., Dan Y Y., Swisshelm K et al. Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice. Hepatology 2008 47 (6) 2078-2088
29. Eder J P., Vande Woude G F., Boerner S A., LoRusso P M. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009 15 (7) 2207-2214
30. Liu M L., Mars W M., Michalopoulos G K. Hepatocyte growth factor inhibits cell proliferation in vivo of rat hepatocellular carcinomas induced by diethylnitrosamine. Carcinogenesis 1995 16 (4) 841-843
31. Nakanishi C, Moriuchi A, Ido A et al. Effect of hepatocyte growth factor on endogenous hepatocarcinogenesis in rats fed a choline-deficient L-amino acid-defined diet. Oncol Rep 2006 16 (1) 25-31
32. Marx-Stoelting P, Borowiak M, Knorpp T, Birchmeier C, Buchmann A, Schwarz M. Hepatocarcinogenesis in mice with a conditional knockout of the hepatocyte growth factor receptor c-Met. Int J Cancer 2009 124 (8) 1767-1772
33. Takami T, Kaposi-Novak P, Uchida K et al. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res 2007 67 (20) 9844-9851
34. Nakatani T, Roy G, Fujimoto N, Asahara T, Ito A. Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprorelin. Jpn J Cancer Res 2001 92 (3) 249-256
35. Naugler W E., Sakurai T, Kim S et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007 317 (5834) 121-124
36. Lee J S., Heo J, Libbrecht L et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006 12 (4) 410-416
37. Shinozuka H, Lombardi B, Sell S, Iammarino R M. Enhancement of DL-ethionine-induced liver carcinogenesis in rats fed a choline-devoid diet. J Natl Cancer Inst 1978 61 (3) 813-817 (Pubitemid 9029113)
38. Hayner N T., Braun L, Yaswen P, Brooks M, Fausto N. Isozyme profiles of oval cells, parenchymal cells, and biliary cells isolated by centrifugal elutriation from normal and preneoplastic livers. Cancer Res 1984 44 (1) 332-338 (Pubitemid 14177759)
39. Yaswen P, Hayner N T., Fausto N. Isolation of oval cells by centrifugal elutriation and comparison with other cell types purified from normal and preneoplastic livers. Cancer Res 1984 44 (1) 324-331 (Pubitemid 14177758)
40. Akhurst B, Croager E J., Farley-Roche C A. et al. A modified choline-deficient, ethionine-supplemented diet protocol effectively induces oval cells in mouse liver. Hepatology 2001 34 (3) 519-522
41. Knight B, Yeoh G C., Husk K L. et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 2000 192 (12) 1809-1818
42. Knight B, Tirnitz-Parker J E., Olynyk J K. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice. Gastroenterology 2008 135 (3) 969-979, 979, e1
43. Tirnitz-Parker J E., Tonkin J N., Knight B, Olynyk J K., Yeoh G C. Isolation, culture and immortalisation of hepatic oval cells from adult mice fed a choline-deficient, ethionine-supplemented diet. Int J Biochem Cell Biol 2007 39 (12) 2226-2239
44. Nakae D, Yoshiji H, Mizumoto Y et al. High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Cancer Res 1992 52 (18) 5042-5045
45. Denda A, Kitayama W, Kishida H et al. Development of hepatocellular adenomas and carcinomas associated with fibrosis in C57BL/6J male mice given a choline-deficient, L-amino acid-defined diet. Jpn J Cancer Res 2002 93 (2) 125-132
46. Webber E M., Wu J C., Wang L, Merlino G, Fausto N. Overexpression of transforming growth factor-alpha causes liver enlargement and increased hepatocyte proliferation in transgenic mice. Am J Pathol 1994 145 (2) 398-408
47. Jhappan C, Stahle C, Harkins R N., Fausto N, Smith G H., Merlino G T. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 1990 61 (6) 1137-1146
48. Lee G H., Merlino G, Fausto N. Development of liver tumors in transforming growth factor alpha transgenic mice. Cancer Res 1992 52 (19) 5162-5170
49. Takagi H, Sharp R, Hammermeister C et al. Molecular and genetic analysis of liver oncogenesis in transforming growth factor alpha transgenic mice. Cancer Res 1992 52 (19) 5171-5177
50. Murakami H, Sanderson N D., Nagy P, Marino P A., Merlino G, Thorgeirsson S S. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res 1993 53 (8) 1719-1723
51. Calvisi D F., Thorgeirsson S S. Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicol Pathol 2005 33 (1) 181-184
52. Calvisi D F., Factor V M., Ladu S, Conner E A., Thorgeirsson S S. Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology 2004 126 (5) 1374-1386
53. Factor V M., Kiss A, Woitach J T., Wirth P J., Thorgeirsson S S. Disruption of redox homeostasis in the transforming growth factor-alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. J Biol Chem 1998 273 (25) 15846-15853
54. Gilbertson D G., Duff M E., West J W. et al. Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem 2001 276 (29) 27406-27414
55. Campbell J S., Hughes S D., Gilbertson D G. et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A 2005 102 (9) 3389-3394
56. Baron U, Gossen M, Bujard H. Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded transactivation potential. Nucleic Acids Res 1997 25 (14) 2723-2729
57. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992 89 (12) 5547-5551
58. Shachaf C M., Kopelman A M., Arvanitis C et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004 431 (7012) 1112-1117
59. Kota J, Chivukula R R., O'Donnell K A. et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009 137 (6) 1005-1017
60. Wang Y, DeMayo F J., Tsai S Y., O'Malley B W. Ligand-inducible and liver-specific target gene expression in transgenic mice. Nat Biotechnol 1997 15 (3) 239-243
61. Chaisson M L., Brooling J T., Ladiges W, Tsai S, Fausto N. Hepatocyte-specific inhibition of NF-kappaB leads to apoptosis after TNF treatment, but not after partial hepatectomy. J Clin Invest 2002 110 (2) 193-202
62. Hayashi S, McMahon A P. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol 2002 244 (2) 305-318
63. Tumurbaatar B, Sun Y, Chan T, Sun J. Cre-estrogen receptor-mediated hepatitis C virus structural protein expression in mice. J Virol Methods 2007 146 (1-2) 5-13
64. Braun L, Goyette M, Yaswen P, Thompson N L., Fausto N. Growth in culture and tumorigenicity after transfection with the ras oncogene of liver epithelial cells from carcinogen-treated rats. Cancer Res 1987 47 (15) 4116-4124
65. Goyette M, Faris R, Braun L, Hixson D, Fausto N. Expression of hepatocyte and oval cell antigens in hepatocellular carcinomas produced by oncogene-transfected liver epithelial cells. Cancer Res 1990 50 (15) 4809-4817
66. Zender L, Xue W, Zuber J et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008 135 (5) 852-864
67. Lee J S., Thorgeirsson S S. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 2004 127 (5, Suppl 1) S51-S55
68. Lee J S., Thorgeirsson S S. Comparative and integrative functional genomics of HCC. Oncogene 2006 25 (27) 3801-3809
69. Zucman-Rossi J, Laurent-Puig P. Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. Pharmacogenomics 2007 8 (8) 997-1003
70. Weiskirchen R, Liedtke C, Trautwein C. When sleeping beauty wakes up and jumps into a cancer-minded environment. Hepatology 2009 49 (6) 2122-2124